NanoMosaic's technology is designed to support upstream and downstream process development, quality control, and release testing.

The FDA AMT designation verifies NanoMosaic platform's ability to enhance efficiency, product quality, and scalability across AAV gene therapy manufacturing.

Gazi University in Ankara has officially launched the production process for Türkiye's first local and national gene therapy research product. The project, which targets rare genetic diseases, is ...

Researchers have completed the first phase of a collaboration integrating robotic cell processing with automated ...

Cellares. Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the ...

Viral vectors and vaccines navigate public distrust while advancing through AI design, COVID response lessons, and promising ...

Thermo Fisher Scientific is continuing its recent layoff spree with a fresh round of cuts tied to a site it’s shuttering in ...

A free two-day event in Cambridge will unite experts to discuss translational advances in cell and gene therapy, spanning rare diseases, cancer immunotherapy, and genome editing.

The program will allow for frequent communication with the FDA, giving manufacturers timely input and guidance regarding the ...

The FDA laid out the qualifications a site would need to qualify for PreCheck on a webpage where companies can also submit ...

Non-specific Endonuclease Market to reach US$ 726.6 Bn by 2036 at 6.5% CAGR, driven by rising biotechnology research, ...

Company expects up to six-month review period per FDA guidelines New longer-term clinical data demonstrating durable positive brain biochemical ...